Talazoparib

Drug Profile

Talazoparib

Alternative Names: BMN-673; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator LEAD Therapeutics
  • Developer BioMarin Pharmaceutical; Medivation; National Cancer Institute (USA); St. Jude Childrens Research Hospital; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Phase I Ewing's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Preclinical Acute myeloid leukaemia; Glioblastoma; Non-small cell lung cancer
  • Discontinued Haematological malignancies

Most Recent Events

  • 15 Dec 2016 Medivation plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater, In adults) in USA and Canada (PO) (NCT02997163)
  • 05 Dec 2016 Phase-II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory, Inoperable/Unresectable, Second-line therapy or greater) in Germany (PO) (EudraCT2016-002036-32)
  • 01 Dec 2016 Medivation withdraws prior to enrolment a phase II trial for Ovarian cancer in USA (NCT02836028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top